

# Preclinical Pharmacokinetics of a Novel Nicorandil Prodrug

Atul Khare<sup>1</sup>, PhD; Pramod Gupta<sup>1</sup>, PhD; Guru Reddy<sup>1</sup>, PhD; Shalabh Gupta<sup>1</sup>, MD

<sup>1</sup>Unicycive Therapeutics, Inc.

## BACKGROUND

- Mitochondrial dysfunction in renal cells play a critical role in the pathophysiology of acute kidney injury (AKI) and chronic kidney disease (CKD)<sup>1</sup>
- Nicorandil, a selective mitochondrial ATP-sensitive potassium channel activator,<sup>2</sup> may be a promising AKI treatment,<sup>3</sup> but its clinical use is limited by serious gastrointestinal side effects and rapid absorption and elimination<sup>4,5</sup>
- UNI-494, a novel nicorandil prodrug designed to improve its pharmacologic properties, may increase the short half-life and improve the safety profile of nicorandil

## OBJECTIVE

We present pharmacokinetic data in dogs for UNI-494

## METHODS

- Groups of 3 beagle dogs were administered a single oral dose of 3, 10, or 30 mg/kg UNI-494 at a volume of 5 mL/kg
- Clinical observations were recorded at approximately 1, 1.5, 2, 3, and 24h post-dose
- Whole blood samples were collected pre-dose and 0.083, 0.25, 0.50, 1, 1.5, 2, 4, 8, and 24h post-dose to analyze systemic exposure to UNI-494 and nicorandil
- Dose and concentration parameters ( $C_{max}$  and AUC) were used to generate linearity plots and calculate the coefficients of determination ( $R^2$ ) and slopes for UNI-494 and nicorandil

## RESULTS


- The mean  $T_{max}$  of nicorandil was 0.7h (3 mg/kg dose), 1.5h (10 mg/kg dose), and 1.3h (30 mg/kg dose), respectively (**Table 1**)
- The mean  $C_{max}$  and AUC of nicorandil increased linearly with UNI-494 dose amounts (**Figure 1 & 2**)

**Table 1.  $C_{max}$ ,  $T_{max}$  and AUC by Dose Group and Analytes in Male Beagle Dogs Following a Single Oral UNI-494 Administration (n=3 per Dose Group)**


	Dose Group (mg/kg)					
	3		10		30	
	UNI-494	NIC <sup>1</sup>	UNI-494	NIC <sup>1</sup>	UNI-494	NIC <sup>1</sup>
$C_{max}$ (ng/mL)	43	1,300	178	3,070	1,500	7,530
$T_{max}$ (Hr)	0.3	0.7	0.3	1.5	0.3	1.3
AUC (Hr*ng/mL)	34	3,400	162	11,400	1,510	38,000

<sup>1</sup> NIC=Nicorandil

**Figure 1. Mean  $C_{max}$  of Nicorandil and UNI-494 by UNI-494 Dose After Single Dosing in Dogs**



**Figure 2. Mean AUC of Nicorandil and UNI-494 by UNI-494 Dose After Single Dosing in Dogs**



## CONCLUSIONS

- Nicorandil was rapidly formed from the prodrug UNI-494
- Mean  $C_{max}$  for nicorandil was >5-fold greater than that of UNI-494, demonstrating the efficient conversion of the prodrug to the active drug
- The conversion was consistent across dose groups

## IMPLICATIONS

- These results indicate that UNI-494 is a rationally designed drug
- Future studies should evaluate this promising treatment in the target population of patients with acute kidney injury

### References:

1. Zhang X, et al. *Int J Mol Sci.* 2021.
2. Kuno A, et al. *Basic Res Cardiol.* 2007.
3. Rabea M, et al. *QJM.* 2021.
4. Frydman AM, et al. *Am J Cardiol.* 1989.
5. SANOFI. IKOREL 10mg and 20mg Tablets (nicorandil) Package Leaflet. 2021.

### Acknowledgments:

Writing support was provided by Xelay Acumen Group, Inc., and funded by Unicycive Therapeutics, Inc.

